Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body’s response to inflammatory diseases.
Aruvian’s R’search presents Analysis of Amgen Inc. A complete and comprehensive analysis of Amgen Inc., includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.
Company analysis from Aruvians includes a history of Amgen Inc., a business segment analysis of the segments Amgen Inc. operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.
A financial analysis of Amgen Inc. is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.
A SWOT Framework Analysis of Amgen Inc. completes this in-depth company analysis.
Our reports have been used by over 10K customers, including:
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018 Summary According to the recently published report ’Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018’; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 17 molecules. Out of which approximately...